<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01493856</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWJ1276002</org_study_id>
    <nct_id>NCT01493856</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276</brief_title>
  <official_title>A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetic characteristics of
      combination of rosuvastatin and CS-866 and DWJ1276 alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCextra</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>18 time points up to 72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin+Olmesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose of Rosuvastatin 20mg and olmesartan medoxomil(CS-866) 40mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DWJ1276</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of DWJ1276</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cresto</intervention_name>
    <description>tablet, rosuvastatin 20mg</description>
    <arm_group_label>Rosuvastatin+Olmesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmetec</intervention_name>
    <description>tablet, olmesartan medoxomil(CS-866) 40mg</description>
    <arm_group_label>Rosuvastatin+Olmesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWJ1276</intervention_name>
    <description>tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg</description>
    <arm_group_label>DWJ1276</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male volunteers aged 20 to 50 years

          2. A subject who provided written informed consent to participate in this study and
             cooperative with regard to compliance with study related constraints

        Exclusion Criteria:

          1. A subject who had any allergic history to any drug.

          2. A subject with sign or symptoms or previously diagnosed disease of liver, kidney,
             neurology, respiratory, endocrinology, hematology, cardiovascular, genitourinary,
             psychology, ophthalmic, dermatology and gastrointestinal function or other significant
             diseases

          3. History or suspicion of current drug abuse

          4. A subject who had received treatment with below listed drug within specified period
             prior to the first dose of study medication

               -  Within 1 month: drug known CYP inducer or inhibitor

               -  Within 2 weeks: Prescribed or herbal medicine

               -  Within 1 weeks: OTC medicine

               -  Within 2 days: Consumption of caffeine

          5. A subject who had participated in any other clinical study within the last 2 weeks

          6. A subject from whom over 400mL of blood was sampled(whole blood donation) within last
             2 weeks or plasma/platelet donation within 1 month.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyungsoo Park, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>YONSEI UNIVERSITY HEALTH SYSTEM (YUHS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Health System (Yuhs)</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2011</study_first_submitted>
  <study_first_submitted_qc>December 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2011</study_first_posted>
  <last_update_submitted>April 2, 2012</last_update_submitted>
  <last_update_submitted_qc>April 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

